CORT · Corcept Therapeutics Inc · Executive Compensation

$115.70 +1.72 (+1.51%) At close · Sep 9

S&P 600 member Russell 1000 member Rebalance outlook locked

Market Cap

$12.32B

108.10M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Joseph K. Belanoff	M.D., Chief Executive Officer and President	$1,182,333	$1,190,000	—	$12,907,718	—	$23,500	$15,303,551
Charles Robb	Chief Business Officer and Secretary	$711,413	$358,000	$124,500	$5,163,087	—	$23,500	$6,380,500
William Guyer	Pharm.D., Chief Development Officer	$706,387	$429,600	$17,871	$5,163,087	—	$23,500	$6,340,445
Sean Maduck	President	$648,860	$261,200	$111,995	$5,163,087	—	$23,500	$6,208,642
Atabak Mokari	Chief Financial Officer and Treasurer	$566,347	$285,000	$97,733	$5,163,087	—	$23,500	$6,135,667

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Joseph K. Belanoff	M.D., Chief Executive Officer and President	$1,140,533	$1,716,000	—	$7,010,548	—	$23,000	$9,890,081
Charles Robb	Chief Business Officer and Secretary	$686,273	$533,572	$91,307	$2,804,219	—	$23,000	$4,138,371
William Guyer	Pharm.D., Chief Development Officer	$656,210	$510,198	—	$2,804,219	—	$23,000	$3,993,627
Sean Maduck	President	$626,148	$471,120	$46,684	$2,804,219	—	$23,000	$3,971,171
Atabak Mokari	Chief Financial Officer and Treasurer	$546,323	$411,060	$72,704	$2,804,219	—	$23,000	$3,857,306

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Joseph K. Belanoff	M.D., Chief Executive Officer and President	$1,083,333	$1,320,000	—	$6,911,901	—	$22,500	$9,337,734
Charles Robb	Chief Business Officer and Secretary	$659,333	$397,200	$112,925	$2,764,760	—	$22,500	$3,956,718
Corcept Endocrinology	—	$601,583	$422,800	$97,288	$2,764,760	—	$22,500	$3,908,931
Sean Maduck	President	$601,583	$422,800	$97,288	$2,764,760	—	$22,500	$3,908,931
William Guyer	Pharm.D., Chief Development Officer	$628,167	$379,800	$60,871	$2,764,760	—	$22,602	$3,856,200
Atabak Mokari	Chief Financial Officer and Treasurer	$524,333	$316,200	$89,314	$2,764,760	—	$22,500	$3,717,107

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Joseph K. Belanoff	M.D., Chief Executive Officer and President	$895,833	$900,000	—	$5,536,424	—	$20,500	$7,352,757
Corcept Endocrinology	—	$572,917	$230,000	$23,954	$2,866,685	—	$20,500	$3,714,056
Sean Maduck	President, Corcept Endocrinology	$572,917	$230,000	$23,954	$2,866,685	—	$20,500	$3,714,056
Charles Robb	Chief Business Officer and Secretary	$627,500	$315,000	$26,240	$2,214,569	—	$20,500	$3,203,809
Hazel Hunt	Ph.D., Chief Scientific Officer	$572,917	$316,250	—	$2,214,569	—	$5,989	$3,109,725
William Guyer	Pharm.D., Chief Development Officer	$572,917	$345,000	$23,954	$1,107,285	—	$20,500	$2,069,656
Atabak Mokari	Chief Financial Officer and Treasurer	$492,750	$247,500	$20,602	$1,107,285	—	$20,500	$1,888,637

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Joseph K. Belanoff	M.D., Chief Executive Officer and President	$843,750	$850,000	—	$9,290,888	—	—	$10,984,638
Atabak Mokari	Chief Financial Officer and Treasurer	$390,000	$219,977	—	$6,411,662	—	—	$7,021,639
William Guyer	Pharm.D. Chief Development Officer	$206,742	$247,500	—	$6,094,183	—	—	$6,548,425
Charles Robb	Chief Business Officer and	$562,575	$337,500	—	$4,357,521	—	—	$5,257,596
Hazel Hunt	Ph.D., Chief Scientific Officer	$517,292	$309,375	—	$3,716,355	—	$6,661	$4,549,683
Sean Maduck	President, Corcept Endocrinology	$519,451	$309,375	—	$3,716,355	—	—	$4,545,181

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Joseph K. Belanoff	M.D., Chief Executive Officer and President	$769,567	$744,000	—	$4,237,643	—	$10,892	$5,762,102
Sean Maduck	President, Corcept Endocrinology	$474,380	$214,157	—	$2,508,404	—	—	$3,196,941
Charles Robb	Chief Business Officer and Secretary	$474,380	$321,236	—	$2,118,822	—	—	$2,914,438
Hazel Hunt	Ph.D., Chief Scientific Officer	$431,873	$243,000	—	$2,084,640	—	$6,180	$2,765,693
Andreas Grauer	M.D., Chief Medical Officer	$454,550	$219,157	—	$1,271,293	—	$118,274	$2,063,274

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Joseph K. Belanoff	M.D., Chief Executive Officer and President	$707,525	$745,290	—	$3,506,155	—	—	$4,958,970
Andreas Grauer	M.D., Chief Medical Officer	$362,267	$243,720	—	$3,115,335	—	$78,245	$3,799,567
Charles Robb	Chief Business Officer and Secretary Amounts shown do not reflect compensation actually received by the named executive officers or the actual value that may be recognized by the named executive officers with respect to these awards in the future. Amounts reported constitute the grant date fair value of option awards as calculated under FASB ASC Topic 718. The relevant assumptions used to calculate the value of the option awards are set forth in Part IV – Item 15 – Financial Statements, Notes to Consolidated Financial Statements, Note 7 – “Preferred Stock and Stockholders’ Equity – Stock-Based Compensation Related to Employee and Director Options” in our Annual Report on Form 10-K for the year ended December 31, 2021. In February 2021, our Board approved a one-time payment of a $10,892 tax gross-up to reimburse Dr. Belanoff for an additional tax liability he incurred arising from a computational error made by the Company in connection with his net (cashless) exercise of stock options in 2019. Dr. Hunt’s base salary and bonus amounts are established in U.S. dollars as presented in the table and converted into pounds sterling on each payroll date using the exchange rate reported by Xe Currency Exchange as of the payment date. Effective March 1, 2021, Mr. Mokari was appointed as our Chief Financial Officer. Mr. Robb served as our Chief Financial Officer until February 28, 2021. Effective March 1, 2021, Mr. Robb was promoted to Chief Business Officer and Secretary.	$456,133	$308,881	—	$1,845,345	—	—	$2,610,359
Sean Maduck	Chief Commercial Officer	$456,133	$308,881	—	$1,476,276	—	—	$2,241,290

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Joseph K. Belanoff	M.D., Chief Executive Officer and President	$679,792	$477,750	—	$5,157,075	—	—	$6,314,617
Charles Robb	Chief Business Officer and Secretary	$436,667	$237,600	—	$2,171,400	—	—	$2,845,667
Sean Maduck	Chief Commercial Officer	$436,667	$198,000	—	$2,171,400	—	—	$2,806,067

Fiscal 2017

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Joseph K. Belanoff	M.D., Chief Executive Officer and President	$647,333	$702,000	—	$2,922,119	—	—	$4,271,452
Sean Maduck	Senior Vice President, Commercial	$397,917	$320,000	—	$2,036,818	—	—	$2,754,735
Charles Robb	Chief Financial Officer and Secretary	$397,929	$320,000	—	$1,062,589	—	—	$1,780,518

Executive changes

Person	Role	Change	Effective	Filed
Kimberly Park	director	Appointed	2026-05-21	2026-05-28
James N. Wilson	director	Appointed	2026-05-21	2026-05-28
Daniel N. Swisher, Jr.	director	Appointed	2026-05-21	2026-05-28
Joseph K. Belanoff, M.D.	director	Appointed	2026-05-21	2026-05-28
David L. Mahoney	director	Appointed	2026-05-21	2026-05-28
Joshua M. Murray	director	Appointed	2026-05-21	2026-05-28
G. Leonard Baker, Jr.	director	Appointed	2026-05-21	2026-05-28
Gregg Alton	director	Appointed	2026-05-21	2026-05-28
Gillian Cannon, Ph.D.	Board of Directors	Resigned	2025-10-10	2025-10-06

Key facts CIK 1088856 CUSIP 218352102 13F (30d) 224 filings 223 filers Visit website Investor relations